StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.78+0.08 (+2.16%)

Close on Nov 18, 2026Market cap $474.43MP/E –Yield –

Earnings

Aquestive Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 3, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$7.60M
-40.6% on a year earlier
Adjusted EPS, Q3 FY2026
-$0.13
-$0.14 a year earlier
Latest guidance
Issued
Nov 3, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Aquestive Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 3, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$7.60M-40.6%-$0.13–Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026after the close$13.80M+38.0%-$0.18-$0.18Release
Q1 FY2026ended Mar 31, 2026May 13, 2026after the close$14.40M+65.5%-$0.07–Release
Q4 FY2025ended Dec 31, 2025Mar 4, 2026after the close$13.00M+9.2%-$0.26-$0.15Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$12.80M-5.2%-$0.14–Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close$10.00M-50.2%-$0.14–Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close$8.70M-28.1%-$0.24–Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025after the close$11.90M-9.8%-$0.19–Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024after the close$13.50M+3.8%-$0.13–Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$20.10M+52.3%-$0.03–Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$12.10M+9.0%-$0.17–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Aquestive Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$46.00M – $50.00M$46.00M – $50.00MReaffirmedAug 11, 2026
Total revenue (in millions)FY2026$46.00M – $50.00M–NewNov 3, 2026
Non-GAAP adjusted EBITDA lossnon-GAAPFY2026-$35.00M – -$30.00M-$35.00M – -$30.00MReaffirmedAug 11, 2026
Non-GAAP adjusted EBITDA loss (in millions)non-GAAPFY2026-$35.00M – -$30.00M–NewNov 3, 2026
cash and cash equivalentsFY2026$70.00M–NewMar 4, 2026

Guidance history

Every forecast Aquestive Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026Non-GAAP adjusted EBITDA loss (in millions)FY2026-$35.00M – -$30.00MNew
Nov 3, 2026Total revenue (in millions)FY2026$46.00M – $50.00MNew
Aug 11, 2026Non-GAAP adjusted EBITDA lossFY2026-$35.00M – -$30.00MReaffirmed
Aug 11, 2026Total revenueFY2026$46.00M – $50.00MReaffirmed
Mar 4, 2026Non-GAAP adjusted EBITDA lossFY2026-$35.00M – -$30.00MNew
Mar 4, 2026cash and cash equivalentsFY2026$70.00MNew
Mar 4, 2026Total revenueFY2026$46.00M – $50.00MNew
Aug 11, 2025Non-GAAP adjusted EBITDA lossFY2025$47.00M – $51.00MNarrowed
Aug 11, 2025Total revenueFY2025$44.00M – $50.00MLowered
Mar 5, 2025Non-GAAP adjusted EBITDA lossFY2025$46.00M – $53.00MNew
Mar 5, 2025Total revenueFY2025$47.00M – $56.00MNew
Aug 6, 2024Non-GAAP adjusted EBITDA lossFY2024$20.00M – $23.00MLowered
Aug 6, 2024Total revenueFY2024$57.00M – $60.00MRaised
May 7, 2024Non-GAAP adjusted EBITDA lossFY2024$22.00M – $26.00MReaffirmed
May 7, 2024Total revenueFY2024$48.00M – $51.00MReaffirmed
Mar 5, 2024Non-GAAP adjusted EBITDA loss (in millions)FY2024$22.00M – $26.00MNew
Mar 5, 2024Total revenue (in millions)FY2024$48.00M – $51.00MNew
Nov 6, 2023Non-GAAP adjusted EBITDA lossFY2023$14.00M – $17.00MLowered
Nov 6, 2023Total revenueFY2023$47.00M – $50.00MRaised
Aug 7, 2023Non-GAAP adjusted EBITDA lossFY2023$19.00M – $22.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Aquestive Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Results
  4. Results
  5. Update
  6. Update
  7. Update
  8. Update
  9. Results
  10. Results
  11. Update
  12. Update
  13. Results
  14. Results
  15. Results

See a number that looks wrong?